Skip to main content

Table 1 Infliximab attrition rates at different time points

From: Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

  Global continuation rates Discontinuation rates
     Inefficacy Elective Safety
Year Percentage 95% CI Percentage 95% CI Percentage 95% CI Percentage 95% CI
1 90.9 88.3 93.5 1.8 0.6 3.0 0.9 0.1 1.7 6.4 4.2 8.6
2 80.7 77.2 84.2 6.4 4.2 8.6 1.4 0.3 2.5 11.5 8.6 14.4
3 69.6 65.5 73.7 11.2 8.4 14.0 3.4 1.8 5.0 15.8 12.5 19.1
4 61.6 57.2 66.0 13.6 10.5 16.7 7.9 5.5 10.3 16.9 13.5 20.3
  1. CI, confidence interval.